Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN30202688
ISRCTN30202688
Completed
Not Applicable

Assessment of the immunogenicity and safety of the Northern Hemisphere 2009/2010-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulations

Crucell, Berna Biotech Ltd (Switzerland)0 sites110 target enrollmentMay 28, 2009
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Crucell, Berna Biotech Ltd (Switzerland)
Enrollment
110
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 28, 2009
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Crucell, Berna Biotech Ltd (Switzerland)

Eligibility Criteria

Inclusion Criteria

  • •1\. Healthy female and male volunteers equal to or older than 18 years of age on the day of enrolment
  • •2\. Written informed consent

Exclusion Criteria

  • •1\. Pregnancy and lactation
  • •2\. Serious adverse reaction to any influenza vaccine

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Assessment of the immunogenicity and safety of the Northern Hemisphere 2010/2011-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulations
ISRCTN89337058Crucell Switzerland AG (Switzerland)110
Completed
Not Applicable
Assessment of the immunogenicity and safety of the Northern Hemisphere 2009/2010-season influenza vaccine in children aged 6 to 35 months in comparison to a commercially available influenza vaccineInfluenzaRespiratoryInfluenza, virus not identified
ISRCTN10483274Berna Biotech Ltd, a Crucell Company (Switzerland)1,239
Completed
Not Applicable
Assessment of the immunogenicity and safety of the Northern Hemisphere 2008/2009-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulations
ISRCTN40098615Crucell, Berna Biotech Ltd (Switzerland)110
Completed
Phase 1
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 2-4-6 months.Prophylaxis against infections diseases: Diphtheria, Tetanus, B. pertussis, H. influenzae type b and hepatitis B.
RPCEC00000103Center for Genetic Engineering and Biotechnology (CIGB).624
Not yet recruiting
Phase 1
ABDALA Clinical StudyCOVID-19SARS-CoV2Disease PreventionCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirus
RPCEC00000346Center for Genetic Engineering and Biotechnology (CIGB), in Havana